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Abstract
Background: CD44 splice variants are long-known as being associated with cell transformation. Recently, the standard form
of CD44 (CD44s) was shown to be part of the signature of cancer stem cells (CSCs) in colon, breast, and in head and neck
squamous cell carcinomas (HNSCC). This is somewhat in contradiction to previous reports on the expression of CD44s in
HNSCC. The aim of the present study was to clarify the actual pattern of CD44 expression in head and neck epithelia.
Methods: Expression of CD44s and CD44v6 was analysed by immunohistochemistry with specific antibodies in primary
head and neck tissues. Scoring of all specimens followed a two-parameters system, which implemented percentages of
positive cells and staining intensities from 2 to +++ (score=%6intensity; resulting max. score 300). In addition, cell surface
expression of CD44s and CD44v6 was assessed in lymphocytes and HNSCC.
Results: In normal epithelia CD44s and CD44v6 were expressed in 60–95% and 50–80% of cells and yielded mean scores
with a standard error of a mean (SEM) of 249.5614.5 and 198611.13, respectively. In oral leukoplakia and in moderately
differentiated carcinomas CD44s and CD44v6 levels were slightly increased (278.967.16 and 242611.7; 291.865.88 and
287.366.88). Carcinomas in situ displayed unchanged levels of both proteins whereas poorly differentiated carcinomas
consistently expressed diminished CD44s and CD44v6 levels. Lymphocytes and HNSCC lines strongly expressed CD44s but
not CD44v6.
Conclusion: CD44s and CD44v6 expression does not distinguish normal from benign or malignant epithelia of the head and
neck. CD44s and CD44v6 were abundantly present in the great majority of cells in head and neck tissues, including
carcinomas. Hence, the value of CD44s as a marker for the definition of a small subset of cells (i.e. less than 10%)
representing head and neck cancer stem cells may need revision.
Citation: Mack B, Gires O (2008) CD44s and CD44v6 Expression in Head and Neck Epithelia. PLoS ONE 3(10): e3360. doi:10.1371/journal.pone.0003360
Editor: Ingemar T. Ernberg, Karolinska Institutet, Sweden
Received June 24, 2008; Accepted September 12, 2008; Published October 9, 2008
Copyright:  2008 Mack et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: olivier.gires@med.uni-muenchen.de
Introduction
CD44, the receptor for hyaluronan [1], is encoded by a single
gene on chromosome 11p13, but actually represents a polymor-
phic group of transmembrane glycoproteins owing to extensive
alternative splicing and post-translational modifications [2]. The
human gene is composed of 19 exons, 10 of which (exons 1–5 and
15–19) are included in the standard form of CD44 termed CD44s.
Isoform CD44s is the smallest and most abundant member of this
polymorphic and monogenic family of proteins. The remaining
exons can be differentially inserted into the mature mRNA via
alternative splicing and may in theory give rise to hundreds of
protein variants. So far approximately 20 CD44 isoforms were
detected in tissues of various origins. In addition to alternative
splicing, diversity is added upon varying N- and O-glycosylation
sites within the extracellular domain of alternatively spliced
products of CD44. In other words, one gene gives rise to a
plethora of proteins with potentially discriminative capacities [3].
CD44 was initially identified in the murine lymphoid compart-
ment as a receptor for extracellular matrix (ECM) [4]. Function-
ally speaking, CD44 is involved in organ integrity through its
ability to contact ECM, is signalling active, and serves as a co-
receptor for numerous transmembrane proteins such as matrix
metalloproteases, members of the ERB family of receptor tyrosine
kinases, and the long-known tumour-associated antigen EpCAM
(CD326, ESA1) [5]. CD44 was in the focus of molecular oncology
in the early 1990s when it was recognized that variants of it, chiefly
CD44v6, regulate tumour progression, invasion, and metastasis
formation [6]. As has been shown for a number of other receptors,
CD44 is dependent on regulated intramembrane proteolysis (RIP)
for full activation of its ECM-binding capacity and especially for
the induction of signaling properties [7–10]. Like the Notch-1
receptor, CD44 is cleaved by ADAM proteases and gamma-
secretases to generate an intracellular domain (CD44-ICD), which
translocates into the nucleus and fosters transcription of genes
from TPA-responsive elements [11].
More recently, the attention paid to CD44s was re-fueled by
reports on its differential expression on cancer stem cells (CSCs)
versus non-tumourigenic carcinoma cells. In breast [12], colon
[13], and HNSCC [14,15], CD44-positivity was a discriminative
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CD44
2 cells were able to recapitulate human tumours in vivo in
immunocompromised mouse recipients. For the specific case of
HNSCC, CD44
+ CSCs were reported to represent a minority
population of less than 10% of the tumour cells in human primary
carcinomas and did hold stem cell-like properties, i.e. self-renewal
and pluripotency to some degree [15,16]. Notedly, the frequency
of CSCs in the CD44-positive fraction of HNSCC was one order
of magnitude below CSCs from colon or breast carcinomas [16].
Additionally, high-level expression of the transcription factor BMI-
1, co-staining with the basal cell marker keratin 5/14, and the lack
of involukrin were indicative markers of CSC property in HNSCC
[14,15]. As for the case of the CSC marker CD133 in colon cancer
[17], the literature on CD44 expression pattern in HNSCC and its
deduced capacity as a CSC marker may appear somewhat
controversial. Several research groups described a robust expres-
sion of CD44s and/or CD44v6 in head and neck, independently
of the malignant state and in a large proportion of tumour cells
[18–21]. This is clearly in contrast to reports on CD44s as being
expressed in less than 10% of HNSCC cells-independently of
additional markers used to characterise this minor but highly
efficacious tumour cell population.
In the present study, we have attempted to clarify this issue and
assessed the expression of CD44s and of tumour-associated splice
variant CD44v6 in epithelia of the head and neck area. Specimens
collection included normal epithelia, oral leukoplakia, and full-
blown primary human carcinomas of varying grading. In the
samples studied, we could not recapitulate a differential expression
of CD44s that would characterise carcinoma cells versus normal
epithelia. CD44s expression in normal and diseased tissue was in
every case above 50% of cells. Although differences between
normal and transformed tissue were higher than for the case of
CD44s, CD44v6 was not an adequate marker either. Further on,
owing to the high incidence of CD44s expression in HNSCC its
value as a major CSC marker for this specific entity may need to
be thoroughly discussed.
Results
CD44 in head and neck epithelia: normal mucosa
Before staining, all samples had been confirmed by two
pathologists during routine clinical diagnosis, both after instanta-
neous section and after embedding. Further on, histopathologic
examination was conducted after hematoxylin/eosin staining (see
Figure S1 for examples of H/E staining). Samples of normal
mucosa (n=10) were stained with CD44s- or CD44v6-specific
antibodies. Cell nuclei were visualised with Mayers hematoxylin.
For a control consecutive sections were stained with murine pre-
immune serum to test for the specificity of the detection system
(examples are shown in Figure S2). In average two thirds of the
thickness of normal mucosa samples were positive for CD44s and
CD44v6 as assessed with a scale in a light microscopy (Figs. 1A
and 2A). Additionally antigen expression was recorded as
percentage of CD44s- or CD44v6-positive cells and according to
expression levels (2 to +++). In normal mucosa a strong (+++) and
primarily plasma membrane-associated expression of CD44s and
CD44v6 was observed in cells of the basal membrane layer and
the suprabasal stratum spinosum (Figs. 1A and 2A). Cells of the
stratum granulosum were almost devoid of CD44s and entirely devoid
of CD44v6. In opposition to carcinoma samples, a cytoplasmic
staining of CD44s and CD44v6 was seen in normal mucosa. This
finding may point towards a more efficient shedding of the CD44
ectodomain, although this remains to be shown experimentally.
The percentage of CD44s and CD44v6-positive cells within
normal epithelia ranged from 60–95% (mean and SEM:
86%63.5%) and 50%–80% (mean and SEM: 66%63.7%),
respectively (Table 1). Standard error of a mean (SEM) was used
in order to include the cohort size into the calculation of
deviations, where SEM represents the standard deviation divided
Figure 1. CD44s expression pattern in head and neck epithelia.
CD44 standard form was visualised upon immunohistochemistry
(reddish brown) in normal epithelium (A), oral leukoplakia (B),
carcinomas in situ (C), grade 2 carcinomas (D), and grade 3 carcinomas
(E). Cell nuclei are stained with hematoxylin (blue). Shown are
representative sections. Arrowheads mark infiltrating lymphocytes with
high-level CD44s expression.
doi:10.1371/journal.pone.0003360.g001
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exhibit both parameters, i.e. percentages of positive cells and
staining intensity at once, we have multiplied both parameters. No
staining scored zero while low to strong expression obtained values
from 1 to 3. Accordingly, maximal resulting score is 300. The
mean scores and SEM for CD44s and CD44v6 in normal mucosa
of the head and neck were 249.5614.5 and 198611.13 (Fig. 3).
CD44 in head and neck epithelia: oral leukoplakia
Oral leukoplakias are at increased risk to progress to carcinoma
in situ and full-blown carcinomas or may even already display
features of cell transformation [22]. Very much in analogy to
normal mucosa, expression of CD44s and CD44v6 in leukoplakias
was strongest in cells of the basal membrane layer. With increasing
differentiation towards cells of the suprabasal layers, expression of
both molecules decreased (Figs. 1B and 2B). CD44s and CD44v6
staining intensity was strong in every one of the leukoplakias tested
(n=22) (Table 1). The percentages of cells that expressed CD44s
and CD44v6 were between 50–100% for both proteins (Mean and
SEM-CD44s: 93%62.38%; CD44v6: 81%63.94%). The mean
scores with SEM for CD44s and CD44v6 in oral leukoplakia were
278.967.16 and 242611.7, respectively. The increase in CD44s
and CD44v6 expression scores in leukoplakia as compared with
normal mucosa was considered significant (Fig. 3) (p-value=0.05
and 0.03, respectively). As mirrored by the increased percentages
of staining, expression of both proteins covered more suprabasal
cell layers, as compared to normal mucosa.
CD44 in head and neck epithelia: squamous cell
carcinomas
Next, we analysed the expression of CD44s and CD44v6 in head
and neck malignancies. Two carcinomas in situ (CIS) stained
moderately to strongly with an average and SEM of 100%60%
and 95%64.95% of cells being positive (Table 1) and yielding scores
with SEM of 250649.9 and 212.5612.5 for CD44s and CD44v6
(Fig. 3). Hence, scores of CIS were comparable to those of normal
mucosa and differences across the sample cohort considered not
significant. In head and neck carcinomas, which have been classified
bytwo pathologistsasmoderately differentiated (G2), all cells (100%)
except for two sample (80% and 90%) expressed CD44s and
CD44v6 to high levels (+++).Only one sample showed a moderate to
strong expression (++/+++) of CD44v6 (Figs. 1D and 2D; Table 1).
Average percentages with SEM were 97%61.9 for CD44s and for
CD44v6. Mean scores with SEM for CD44s and CD44v6 were
291.865.88 and 287.366.88 and both were significantly higher
than healthy mucosa (Fig. 3).
For the case of carcinomas diagnosed as poorly differentiated
(G3) staining of CD44s and CD44v6 was characterised by a higher
inter-tumour heterogeneity. In other words, percentages of
positive cells varied from 60%–100% for both proteins and
expression levels ranged from negative (2), weak (+), and
moderate (++) to strong (+++) (Figs. 1E and 2E; Table 1). These
differences as compared to G2 graded carcinomas were also
reflected by significantly lower scores along with higher SEMs
(208.8616.68 and 168.8620.6, respectively). Figure 3 shows
additional changes in expression scores that were considered
significant or highly significant.
CD44 in lymphoid cells
CD44s has been initially described in lymphocytes while
CD44v6 was described as being expressed more specifically in
epithelia and, more precisely, in tumours thereof [3]. It could
already be seen in Figures 1 and 4 that CD44s was not solely
expressed in epithelia in head and neck tumour specimens. Rather
was CD44s also strongly present at the plasma membrane of
lymphocytic cells and was loosely stained in the stroma, too (Figs. 1
and 4, and data not shown). Much in contrast to this, CD44v6 was
exclusively expressed on epithelial cells although massive lymphoid
infiltrates could be detected (Figs. 2 and 4). For this reason, we
compared CD44s and CD44v6 staining directly in consecutive
serial sections of the same samples. In one case of CIS,
Figure 2. CD44v6 expression pattern in head and neck
epithelia. CD44 splice variant 6 was visualised upon immunohisto-
chemistry (reddish brown) in normal epithelium (A), oral leukoplakia
(B), carcinomas in situ (C), grade 2 carcinomas (D), and grade 3
carcinomas (E). Cell nuclei are stained with hematoxylin (blue). Shown
are representative sections.
doi:10.1371/journal.pone.0003360.g002
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Tissue Grading CD44s (% of cells) Intensity Score CD44v6 (% of cells) Intensity Score
NE /9 5 % +++ 285 50% +++ 150
NE /6 0 % ++/+++ 150 70% +++ 210
NE /9 5 % +++ 285 80% +++ 240
NE /8 0 % ++/+++ 200 60% +++ 180
NE /8 0 % +++ 240 70% +++ 210
NE /9 5 % +++ 285 80% +++ 240
NE /8 0 % +++ 240 60% +++ 180
NE /9 5 % +++ 285 80% +++ 240
NE /9 5 % +++ 285 60% +++ 180
NE /8 0 % +++ 240 50% +++ 150
LP / 100% +++ 300 80% +++ 240
LP /9 0 % +++ 270 80% +++ 240
LP / 100% +++ 300 95% +++ 285
LP /9 0 % +++ 270 80% +++ 240
LP /8 0 % +++ 240 80% +++ 240
LP / 100% +++ 300 50% +++ 150
LP /9 0 % +++ 270 50% +++ 150
LP / 100% +++ 300 50% +++ 150
LP /9 5 % +++ 285 80% +++ 240
LP / 100% +++ 300 90% +++ 270
LP /9 0 % +++ 270 90% +++ 270
LP /9 0 % +++ 270 90% +++ 270
LP / 100% +++ 300 90% +++ 270
LP /5 0 % +++ 150 50% +++ 150
LP / 100% +++ 300 100% +++ 300
LP /9 0 % +++ 270 90% +++ 270
LP /9 0 % +++ 270 80% +++ 240
LP / 100% +++ 300 100% +++ 300
LP / 100% +++ 300 100% +++ 300
LP / 100% +++ 300 100% +++ 300
LP /9 0 % +++ 270 50% +++ 150
LP / 100% +++ 300 100% +++ 300
CIS / 100% ++ 200 100% ++ 200
CIS / 100% +++ 300 90% ++/+++ 225
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% +++ 300
CA 29 0 % +++ 270 90% +++ 270
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% +++ 300
CA 28 0 % +++ 240 80% +++ 240
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% +++ 300
CA 2 100% +++ 300 100% ++/+++ 250
CA 37 0 % +++ 210 60% 2/+++ 90
CA 38 0 % +/+++ 160 90% ++ 180
CA 3 100% +++ 300 100% ++ 200
CA 38 0 % ++/+++ 200 60% 2/+++ 90
CA 37 0 % ++/+++ 175 60% 2/++ 60
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and separated by interstitial lymphocytes. This specific case was
chosen for comparison of CD44s and CD44v6 expression.
CD44v6 was strictly detected in epithelial cells in the normal
mucosa and in CIS cells (Fig. 4A right panel). Lymphocytic cells
lining vessels and the CIS were devoid of CD44v6. In sharp
contrast, CD44s was present in CIS and normal epithelium, but
likewise in infiltrating lymphoid cells (Fig. 4A, left panel). The
same situation was encountered in HNSCC, where CD44v6
discriminated between carcinoma cells (positive), stroma and
lymphocytic cells (negative) (Fig. 4B, right panel). Oppositely,
CD44s was present in carcinoma cells and in infiltrating cells to
even higher levels (Fig. 4B, left panel). Only exceptions were areas
of horn-pearl forming and keratinising tumour cells, which hardly
stained for CD44s or CD44v6 (Fig. 4B). These findings were
further substantiated upon staining of peripheral blood mononu-
clear cells. CD44s but not CD44v6 was expressed on cells of the
lymphocytic gate and the monocytic/granulocytic gate (Fig. 5A). B
blasts, which are human B cells that have been conditionally
immortalised upon permanent CD40 ligation [23], expressed
CD44s to substantial amounts but entirely lacked CD44v6
(Fig. 5B). Interestingly, Epstein-Barr virus transformed lympho-
blastoid cell lines (LCLs) expressed large amounts of CD44s and to
varying extent also CD44v6 (Fig. 5C). HNSCC FaDu cells also
strongly expressed CD44s, as was described elsewhere [14], and
lacked CD44v6 Fig. 5D.
Discussion
It was roughly a decade ago when scientists revisited the view of
tumour origination for the case of leukemia. Coming from a rather
stochastic model, where every single cell of a tumour would be
equipped with tumourigenic potential, scientists moved towards a
more hierarchical model, with only a subset of cells within malignant
tissue that are able to generate tumours. In this model so-called
cancer stem cells, CSCs, are the founders of tumours. CSCs
display to some degree properties of normal stem cells including
self-renewal, pluripotency, and limitless proliferation [24]. The
remaining cancer cells that lack these properties are characterised
by a restricted or even no growth capacity at all in vivo. Data
supporting the notion of CSCs in solid tumours emerged in early
2000, when Al-Hajj et al. characterised breast cancer-initiating





high cell surface phenotype. Amazingly, as few as 100 cells sufficed
to recapitulate human carcinogenesis in vivo upon inoculation in
immunodeficient murine recipients. Importantly, resulting tu-
Table 1. cont.
Tissue Grading CD44s (% of cells) Intensity Score CD44v6 (% of cells) Intensity Score
CA 36 0 % ++/+++ 150 100% ++ 200
CA 36 0 % ++ 120 70% +/++ 105
CA 38 0 % ++ 160 80% ++ 160
CA 38 0 % +++ 240 60% ++/+++ 150
CA 3 100% +++ 300 100% +++ 300
CA 3 100% ++ 200 80% +/+++ 160
CA 3 100% ++ 200 80% ++/+++ 200
CA 3 100% +++ 300 100% +++ 300
2 no staining; + weak; ++ moderate; +++ strong.
The score incorporates the percentage of cells expressing the given antigen multiplied by the staining intensity (0–3). Grading is according to UICC convention.
doi:10.1371/journal.pone.0003360.t001
Figure 3. CD44s and CD44v6 expression scores in head and
neck epithelia. The expression scores of CD44s (upper) and CD44v6
(lower) implement expression intensity and percentages of positive
cells (score=staining intensity6% positive cells; max score 300). Shown
are the mean scores with standard deviations. Where indicated,
differences across specimen groups were significant (* p,0.05; **
p,0.005). NE: normal epithelium; LP: leukoplakia; CIS: carcinoma in situ;
Ca-G2: grade 2 carcinoma; Ca-G3: grade 3 carcinoma.
doi:10.1371/journal.pone.0003360.g003
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in the primary tumours, and could be serially transplanted. The
interacting protein CD44 and EpCAM [5] were part of the CSC
signature in not only breast cancer but also colon [13]. With
respect to EpCAM (ESA-1) [25,26], it was consistently the
phenotype of high-level expression that characterised CSCs. This
was markedly different for CD44, whose simple expression
discriminated CSCs from non-tumourigeneic cells in head and
neck malignancies [14–16].
In the present study the expression of the standard form CD44s
and the tumour-associated alternative splice variant CD44v6 were
assessed in epithelia of the head and neck, including pre-
malignancies and full-blown carcinomas. Surprisingly and some-
what in contradiction to available data [18–20], CD44s was
abundantly expressed in most tumour cells within HNSCC.
Percentages of CD44s-positive cells in normal head and neck
epithelial cells ranged from 60% to 95% with strong staining
intensities. In moderately differentiated HNSCC, CD44s was
present in 80–100% of tumour cells and additionally in virtually all
infiltrating lymphocytes. Prince et al. reported on thirty-three
patients suffering from diverse HNSCC including tongue, larynx,
floor of the mouth, oropharynx, and maxillary sinus [15,16]. In
these cases CD44s percentages within tumours ranged from 0.1%
to 41.72%, hence low levels, and were typically below 10% of the
total tumour cell population, which remained unseen in our
specimens. It is important to note that the same antibody specific
for CD44s was used in both studies and that antibody
concentrations used herein were down to 100-fold lower. Kawano
et al. on the other hand described that 75.4% of samples of patients
suffering from mesopharyngeal cancers (n=57) were positive for
CD44s and 78.9% were positive for CD44v6 [27]. These
dimensions fit the percentages of CD44s and CD44v6 expressing
cells assessed herein.
The alternative splice variant CD44v6 showed an expression
pattern similar to CD44s in epithelial areas, independently of the
transformation status. We could only detect an over-expression of
CD44v6 in grade 2 carcinomas as compared to normal
epithelium. However, in contrast to CD44s, CD44v6 was not
expressed in infiltrating lymphocytic cells but remained restricted
to epithelia. CD44v6 was of interest owing to its potential to
increase proliferation via the MAP kinase and Ras signalling
pathways [28,29]. Also, CD44v6 expression was correlated with a
reduced disease-free survival in laryngeal malignancies [30]. We
could however not confirm a clear association of CD44v6 with
malignancy for HNSCC.
In summary, we show that CD44s is abundantly expressed in
head and neck carcinomas. This is in sharp contrast to previous
reports on CD44s and cancer stem cells in HNSCC, and may rely
on different technologies used to visualise CD44s-positive cells, i.e.
flow cytometry versus immunohistochemistry. Similar inconsisten-
cies have been reported recently concerning CD133, a marker for
CSCs in numerous entities including colon, brain, prostate, liver,
and pancreas [17]. Shmelkov et al. demonstrated that CD133 is
ubiquitously expressed in murine and human colon carcinoma
cells [17]. Further on cancer stem cell potential was not restricted
to CD133-positive cells. Both, CD133
+ and CD133
2 cells bore
long-term tumourigenic potential in immunodeficient mice.
Though the principle and existence of CSCs remains undoubted,
the actual nature of markers of tumour-initiating cells, their usage,
expression, and signification need more attention.
Figure 4. Comparative expression of CD44s and CD44v6 in head and neck epithelia. CD44s and CD44v6 (reddish brown) were visualised
in consecutive serial sections of a carcinoma in situ (A) and one carcinoma (B). Cell nuclei are stained with hematoxylin (blue). CIS: carcinoma in situ;
ve: vessel; muc: mucosa; int: interstitium; ca: carcinoma; HP: horn-pearl forming keratinised tumour cells. Shown are representative sections.
doi:10.1371/journal.pone.0003360.g004
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Tissue samples
Samples of normal mucosa (n=10), oral leukoplakia (n=22),
carcinomas in situ (CIS) (n=2), moderately differentiated carcino-
mas (G2; n=11), and poorly differentiated carcinomas (G3;
n=13) were obtained after written informed consent during
routine surgery according to institutional ethics approval by the
ethics committee of the local medical faculty (Ethikkommision der
Medizinischen Fakulta ¨t der Ludwig-Maximilians-Universita ¨t Mu ¨nchen). All
samples were embedded in tissue-tek (Sakura, Fintek, NL) and
snap-frozen in liquid nitrogen before processing to 4mm thick
consecutive cryosections. All specimens had been examined and
confirmed by two pathologists during routine clinical diagnosis
and histopathologic examination after hematoxylin/eosin staining
(see Figure S2 for examples of H/E staining).
Immunohistochemistry
The mouse anti-human CD44s (mouse IgG2b, lot # 86572, BD
Pharmingen, Heidelberg, Germany) and anti-human CD44v6
(mouse IgG1, lot # 212115, Novocastra, New Castle upon Tyne,
UK) primary antibodies were used. Immunostaining was per-
formed using the avidin-biotin-peroxidase complex method
(Vectastain, Vector laboratories, Burlingame, CA, USA) according
to the manufacturers protocol. Briefly, after fixation in acetone
(10 min), endogenous peroxidase activity was inhibited upon
treatment with 0.03% H2O2/PBS (10 min). Before specific
staining, unspecific antigenic sites were blocked with normal horse
Figure 5. Comparative expression of CD44s and CD44v6 in lymphoid cells. Cell surface expression of CD44s and CD44v6 were assessed on
peripheral blood mononuclear cells (A), B blast clones (B), lymphoblastoid cell clones (C), and HNSCC FaDu cells (D) using specific antibodies and
flow cytometry. Red line: control; black line: specific antibody. LCL: lymphoblastoid cell lines. Shown are representative results of two independent
measurements.
doi:10.1371/journal.pone.0003360.g005
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antibody for 1 hour at room temperature (RT) followed by
incubation with biotinylated anti-mouse immunoglobulins and
then with avidin-biotin-peroxidase complex (30 minutes at RT for
each step). After each step, sections were washed with PBS.
Specific peroxidase activity was visualized with 0.05% 3-amino-9-
ethylcarbazol (Sigma, Deisenhofen, Germany) and 0.02% H2O2/
0,1M Na-acetat buffer pH5.5 as a substrate. Counterstaining was
performed with Mayers hematoxylin and eosin. As a negative
control, staining was performed with mouse pre-immune serum
instead of specific antibodies. Assessment of percentages of positive
cells was performed across the entire sample in a blinded fashion
upon light microscopy by two investigators and is given as the
mean of both percentages assessed in steps of 5%.Percentages of
staining refer to epithelial/tumour cells within samples.
Flow cytometry
Peripheral blood mononuclear cells, B blasts, lymphoblastoid cell
lines, or head and neck squamous cell carcinoma cells FaDu were
stained with CD44s- or CD44v6-specific antibodies in combination
with a FITC-conjugated anti-mouse secondary antibody. Fluores-
cence intensities were assessed after washing in PBS in a
FACScalibur device (Becton Dickinson, Heidelberg, Germany).
Supporting Information
Figure S1 Hematoxylin/eosin staining was performed on kryosec-
tion of normal epithelium, carcinoma in situ, grades 2 and 3
carcinomas. Stained samples were examined by two pathologists and
different areas within specimens were denoted. Shown are
representativeexamplesoftheentirecohortusedinthepresentstudy.
Found at: doi:10.1371/journal.pone.0003360.s001 (4.16 MB TIF)
Figure S2 Negative controls for immunohistochemistry. Normal
mucosa and grade 2 carcinoma were stained with murine pre-
immune serum in combination with standardised detection
systems. Nuclei were counter-stained with hematoxylin. Shown
are representative results from the cohort analysed in the present
study.
Found at: doi:10.1371/journal.pone.0003360.s002 (1.57 MB TIF)
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